Clinical trials: Viral Load
HIV, Viral Load
East Africa Point of Care Viral Load Study
The purpose of EAPoC-VL project is to examine the feasibility, acceptability, and effectiveness of using point of care viral load (PoC VL) monitoring to improve viral load suppression among children, adolescents and young people…
- Conditions
- HIV, Viral Load, Point of Care Monitoring
- Trial name
- EAPoC-VL (NCT05048472)
- Testing
- Abbott HIV-1/2 VL Point of care Device
- Where
- 7 sites in Kenya, Rwanda and 2 more
- Volunteers
- 956 people, healthy volunteers welcome
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
HIV Infections
Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand
Since 2004, the Thai Ministry of Public Health has massively scaled up antiretroviral treatment programs to provide therapy to more than 80,000 patients with partial support of the Global Fund to fight AIDS, Tuberculosis and…
- Trial name
- NCT00433030
- Where
- 38 sites in Thailand
- Volunteers
- 2,816 people
- Sponsor
- Institut de Recherche pour le Developpement
Covid19
Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19
Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.
- Trial name
- NCT04349592
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- Qatar
- Volunteers
- 456 people
- Sponsor
- Hamad Medical Corporation
HIV Infections
Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment
The purpose of this study is to test another way to control the amount of HIV in the blood (viral load). Studies show that stopping all anti-HIV drugs for a time before switching to new anti-HIV drugs may improve the response in…
- Trial name
- NCT00011128
- Testing
- Antiretroviral Treatment Interruption
- Where
- 30 sites in United States, Puerto Rico
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
4-Day-A-Week Treatment Plan for HIV Infected Adolescents
This study will determine if taking anti-HIV drugs 4 days a week will control HIV-1 viral replication in patients who have already had at least 6 months of documented viral suppression with full-time treatment.
- Trial name
- NCT00068809
- Testing
- Short Cycle Antiretroviral Therapy
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 31 people
- Sponsor
- University of North Carolina, Chapel Hill
COVID-19
Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions
Background: COVID-19 is a worldwide pandemic and currently there is no effective therapy or vaccine. SARS-CoV-2, the virus that causes the COVID-19 respiratory infection, appears to be very contagious however all the modes of…
- Trial name
- NCT04348240
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Covid19, SARS-CoV-2
Asymptomatic SARS-CoV-2 Detection in Children
The primary objective of this study is quantify the transmission risk posted by SARS-CoV-2 in pre/asymptomatic infected children in order to inform the public health response to the COVID-19 pandemic.
- Trial name
- NCT04853316
- Where
- 5 sites in United States, Canada
- Volunteers
- 372 people
- Sponsor
- University of Calgary
HIV Infections
Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection
The purpose of this study is to compare changes in HIV levels and certain immune cells among patients at different stages of HIV infection.
- Trial name
- NCT00006443
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART
To determine the short-term virologic and immunologic effects of using plasma genotypic antiretroviral resistance testing (GART) results (interpreted by study virologists AS PER AMENDMENT 9/17/97) in the management of therapy for…
- Trial name
- NCT00000874
- Where
- 24 sites in United States
- Volunteers
- 148 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma, Hepatitis C Antibodies
Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy
In last few years, most researches about hepatic complication after chemotherapy focused on hepatitis B virus (HBV). With adequate prophylaxis and monitor, HBV-related hepatitis flares can be prevented.
- Conditions
- Lymphoma, Hepatitis C Antibodies, Drug Therapy
- Trial name
- NCT02588560
- Volunteers
- 38 people
- Sponsor
- Chang Gung Memorial Hospital
Cytomegalovirus Infections, HIV-1-infection
Cytomegalovirus Infection in Patients With HIV-1 Infection
The purpose of this study is to assess the level of CD4 and CD8 T cell activation in an observational cohort study of HIV-1 patients, virosuppressed on combined antiretroviral therapy (< 50 copies/ml) for at least 2 years and to…
- Trial name
- ACTHIV (NCT04067869)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 392 people
- Sponsor
- University Hospital, Bordeaux
HIV Infections
The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
To evaluate the safety and tolerance of adefovir dipivoxil and indinavir administered orally in combination with zidovudine, lamivudine, or stavudine in HIV-infected patients with CD4 cell counts >= 100 cells/mm3 and an HIV-1 RNA…
- Trial name
- NCT00002379
- Testing
- Indinavir sulfate, Levocarnitine, Adefovir dipivoxil
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
The purpose of this study is to see whether taking indinavir (IDV) plus ritonavir (RTV) plus stavudine (d4T) plus lamivudine (3TC) 2 times each day is safe and can lower the level of HIV in the blood.
- Trial name
- NCT00002241
- Testing
- Indinavir sulfate, Ritonavir, Lamivudine
- Where
- 18 sites in United States
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for…
- Trial name
- EMPATHY (NCT04828161)
- Testing
- ensovibep
- Where
- 48 sites in United States, Hungary and 3 more
- Volunteers
- 407 people
- Sponsor
- Novartis Pharmaceuticals
Virus Infection, RNA, Effect of Drug
Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx
The COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War-II.Corona virus is transmitted via respiratory droplets or aerosol, produced from sneezing or…
- Conditions
- Virus Infection, RNA, Effect of Drug, Efficacy, Self
- Trial name
- COVID-19 (NCT04872686)
- Testing
- 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient, 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity, 0.6% PVP-I Oral and nasal spray to healthy volunteer
- Where
- 4 sites in Bangladesh
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- DR. MALA KHAN
HIV Infection
Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load
This 2-part study will examine 1) the immune response to influenza (flu) vaccine in HIV-infected patients, and 2) the effect of flu vaccine on HIV viral loads.
- Trial name
- NCT00025922
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis B
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
This is a multicenter, randomized, double-blind, placebo-controlled Phase III study with an open-label extension. The purpose is to evaluate efficacy and safety in adult patients with chronic hepatitis B virus infection who have…
- Trial name
- NCT07797231
- Testing
- TQA3605 tablets, Entecavir dispersible tablets, Tenofovir Disoproxil Fumarate Tablets
- Where
- 77 sites in China
- Volunteers
- 930 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HIV Infections
The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give calanolide A to HIV-infected adults who have not used anti-HIV drugs in the past.
- Trial name
- NCT00005120
- Testing
- Calanolide A
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sarawak MediChem Pharmaceuticals
HIV, Pregnancy
Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection
The current available antiretroviral (ARV) agents make possible a successful treatment of virtually all HIV-infected patients, even those heavily experienced subjects, with a history of previous failure to ARV drugs of different…
- Trial name
- PregnantHIV (NCT01854762)
- Testing
- Raltegravir, Lopinavir/Ritonavir
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Fundação Bahiana de Infectologia
HIV Infection
Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian Populations
This is a cluster randomized trial to evaluate the effectiveness of integrated care centers (ICC) to improve access to HIV testing, prevention services, and treatment among high-risk populations of injection drug users (IDU) and…
- Trial name
- NCT01686750
- Testing
- Integrated care centers
- Where
- India
- Volunteers
- 21,726 people
- Sponsor
- Johns Hopkins University